We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+12.62%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$615M
AUM Growth
+$85.2M
Cap. Flow
+$34.9M
Cap. Flow %
5.67%
Top 10 Hldgs %
53.32%
Holding
366
New
100
Increased
78
Reduced
73
Closed
88

Top Buys

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$19.3M
2
ASND icon
Ascendis Pharma A/S
ASND
+$14.9M
3
ZURA icon
Zura Bio
ZURA
+$14.1M
4
AAM
AA Mission Acquisition Corp
AAM
+$10.1M
5
ZLAB icon
Zai Lab
ZLAB
+$9.65M

Top Sells

Rank Stock Value
1
PTGX icon
Protagonist Therapeutics
PTGX
+$25.2M
2
ROIV icon
Roivant Sciences
ROIV
+$12.8M
3
MRK icon
Merck
MRK
+$8.86M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$8.32M
5
QURE icon
uniQure
QURE
+$5.48M

Sector Composition

Rank Sector Weight
1 Healthcare 85.92%
2 Financials 3.35%
3 Communication Services 0.57%
4 Technology 0.47%
5 Utilities 0.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PMVP icon
176
PMV Pharmaceuticals
PMVP
$64.5M
$151K 0.02%
101,008
+51,008
+102% +$78.8K
IOVA icon
177
Iovance Biotherapeutics
IOVA
$2.66B
$147K 0.02%
15,700
-6,700
-30% -$63.5K
PGRU
178
DELISTED
PropertyGuru Group Limited
PGRU
$132K 0.02%
+20,000
New +$124K
BHVN icon
179
Biohaven
BHVN
$2.2B
$132K 0.02%
+2,637
New +$103K
MRK icon
180
Merck
MRK
$317B
$129K 0.02%
1,140
-74,610
-98% -$8.86M
PRM icon
181
Perimeter Solutions
PRM
$6.02B
$121K 0.02%
+9,000
New +$93.2K
AMPY icon
182
Amplify Energy
AMPY
$171M
$121K 0.02%
18,475
+15,547
+531% +$108K
TGTX icon
183
TG Therapeutics
TGTX
$7.52B
$117K 0.02%
5,000
-589
-11% -$12.9K
QNCX icon
184
Quince Therapeutics
QNCX
$29.6M
$111K 0.02%
715
+250
+54% +$35.8K
XAIR icon
185
Beyond Air
XAIR
$4.11M
$109K 0.02%
705
-2,358
-77% -$453K
ACRS icon
186
Aclaris Therapeutics
ACRS
$813M
$104K 0.02%
+90,000
New +$110K
ANIP icon
187
ANI Pharmaceuticals
ANIP
$1.77B
$101K 0.02%
+1,700
New +$104K
RXRX icon
188
Recursion Pharmaceuticals
RXRX
$1.71B
$98.8K 0.02%
+15,000
New +$108K
SYRS
189
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$96.8K 0.02%
+45,000
New +$162K
SRRK icon
190
Scholar Rock
SRRK
$6.24B
$96.1K 0.02%
12,000
– –
LQDA icon
191
Liquidia Corp
LQDA
$7.89B
$92.8K 0.02%
+9,285
New +$101K
NKTR icon
192
Nektar Therapeutics
NKTR
$2.51B
$88.1K 0.01%
+4,517
New +$86.1K
ESTA icon
193
Establishment Labs
ESTA
$2.33B
$86.5K 0.01%
+2,000
New +$87K
BMRN icon
194
BioMarin Pharmaceuticals
BMRN
$12.1B
$84.3K 0.01%
+1,200
New +$100K
CRBP icon
195
Corbus Pharmaceuticals
CRBP
$184M
$82.5K 0.01%
4,000
-8,000
-67% -$409K
RCKT icon
196
Rocket Pharmaceuticals
RCKT
$379M
$79.4K 0.01%
4,300
+4,200
+4,200% +$86K
AITR
197
DELISTED
AI Transportation Acquisition Corp
AITR
$78.6K 0.01%
+7,500
New +$78.1K
IMA
198
ImageneBio Inc
IMA
$65.3M
$77.2K 0.01%
3,720
-170
-4% -$3.44K
APLT
199
DELISTED
Applied Therapeutics
APLT
$74.2K 0.01%
8,727
-312,000
-97% -$1.84M
VIGL
200
DELISTED
Vigil Neuroscience
VIGL
$73.9K 0.01%
+21,737
New +$80.5K
6 7
8
9 10

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return

ADAR1 Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, ADAR1 Capital Management held 366 positions worth $615M, up 16% from $530M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

ADAR1 Capital Management deployed $34.9M of net new capital in Q3 2024, opening 100 new positions and adding to 78 existing holdings. Its largest new stake was Zura Bio: 3,770,649 shares worth $15.3M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 80% a quarter earlier, followed by Financials and Communication Services.

On the sell side, the largest reduction was Protagonist Therapeutics, an estimated $25.2M trimmed.

  • ADAR1 Capital Management's largest Q3 2024 buy was Zura Bio: 3,770,649 shares worth $15.3M.
  • ADAR1 Capital Management added most to Immunovant in Q3 2024, an estimated $19.3M increase.
  • ADAR1 Capital Management's biggest Q3 2024 reduction was Protagonist Therapeutics, cutting an estimated $25.2M.
  • ADAR1 Capital Management fully exited uniQure in Q3 2024, selling an estimated $5.48M.
  • ADAR1 Capital Management's ten largest holdings make up 53% of its $615M portfolio in Q3 2024.
  • ADAR1 Capital Management opened 100 new positions and closed 88 in Q3 2024.
  • ADAR1 Capital Management's portfolio value rose 16% quarter-over-quarter to $615M.

Based on ADAR1 Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.